Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Drug Metabolism and Transport
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1466877
This article is part of the Research Topic ADME of Drugs to Treat Infectious Diseases View all 5 articles

Contribution and expression of renal drug transporters in renal cell carcinoma

Provisionally accepted
Yawen Zuo Yawen Zuo 1*Tong Li Tong Li 1*Shilei Yang Shilei Yang 1Kexin Lin Kexin Lin 1*Xiaorui Kong Xiaorui Kong 1*Deshi Dong Deshi Dong 1Fang Liu Fang Liu 2*Yanna Zhu Yanna Zhu 1*
  • 1 Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, Dalian, China, Dalian, Liaoning Province, China
  • 2 Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China

The final, formatted version of the article will be published soon.

    Renal cell carcinoma (RCC) is a common substantive tumor. According to incomplete statistics, RCC incidence accounts for approximately 90 % of renal malignant tumors, and is the second most prevalent major malignant tumor in the genitourinary system, following bladder cancer. Only 10-15 % of chemotherapy regimens for metastatic renal cell carcinoma (mRCC) are effective, and mRCC has a high mortality. Drug transporters are proteins located on the cell membrane that are responsible for the absorption, distribution, and excretion of drugs. Lots of drug transporters are expressed in the kidneys.Changes in carrier function weaken balance, cause disease, or modify the effectiveness of drug treatment. The changes in expression of these transporters during cancer pathology results in multidrug resistance to cancer chemotherapy. In the treatment of RCC, the study of drug transporters helps to optimize treatment regimens, improve therapeutic effects, and reduce drug side effects. In this review, we summarize advances in the role of renal drug transporters in the genesis, progression, and treatment of RCC.

    Keywords: Renal cell carcinoma, Renal tubular epithelial cell, drug transporters, Therapeutic effect, adverse reaction

    Received: 18 Jul 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Zuo, Li, Yang, Lin, Kong, Dong, Liu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yawen Zuo, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, Dalian, China, Dalian, Liaoning Province, China
    Tong Li, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, Dalian, China, Dalian, Liaoning Province, China
    Kexin Lin, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, Dalian, China, Dalian, Liaoning Province, China
    Xiaorui Kong, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, Dalian, China, Dalian, Liaoning Province, China
    Fang Liu, Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
    Yanna Zhu, Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, 116011, Dalian, China, Dalian, Liaoning Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.